Freddie C. Hamdy
A5012694886- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Cancer, Lipids, and Metabolism
- Genetic Associations and Epidemiology
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Colorectal Cancer Screening and Detection
- Molecular Biology Techniques and Applications
- Cancer-related molecular mechanisms research
- Nutritional Studies and Diet
- Genetic factors in colorectal cancer
- Bone health and treatments
- Cancer Risks and Factors
- Global Cancer Incidence and Screening
- Cancer, Hypoxia, and Metabolism
- Nutrition, Genetics, and Disease
- Urologic and reproductive health conditions
- Statistical Methods in Clinical Trials
- Growth Hormone and Insulin-like Growth Factors
- Ethics in Clinical Research
- DNA Repair Mechanisms
- Urinary and Genital Oncology Studies
- Metabolism, Diabetes, and Cancer
University of Oxford
2016-2025
Churchill Hospital
2011-2025
Oxford University Hospitals NHS Trust
2015-2025
John Radcliffe Hospital
2014-2024
Nuffield Orthopaedic Centre
2011-2024
Cancer Research UK Oxford Centre
2010-2023
Urological Society of Australia and New Zealand
2020-2023
Nuffield Health
2012-2023
Oxfam
2023
Liechtenstein Institute
2023
The comparative effectiveness of treatments for prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertain.
Robust data on patient-reported outcome measures comparing treatments for clinically localized prostate cancer are lacking. We investigated the effects of active monitoring, radical prostatectomy, and radiotherapy with hormones outcomes.
The aim of this study was to investigate the hypothesis that changes in circulating microRNAs (miRs) represent potentially useful biomarkers for diagnosis, staging and prediction outcome prostate cancer. Real-time polymerase chain reaction analysis 742 miRs performed using plasma-derived microvesicles 78 cancer patients 28 normal control individuals identify differentially quantified miRs. A total 12 were compared with controls, including 9 without metastases. In all, 11 present...
Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer was diagnosed 2664 men. Of these men, 1643 were enrolled trial to evaluate effectiveness treatments, with 545 randomly assigned receive active monitoring, 553 undergo prostatectomy, radiotherapy.
Metastatic progression of advanced prostate cancer is a major clinical problem. Identifying the cell(s) origin in and its distant metastases may permit development more effective treatment preventive therapies. In this study, aldehyde dehydrogenase (ALDH) activity was used as basis to isolate compare subpopulations primary human cells cell lines. ALDH-high displayed strongly elevated clonogenicity migratory behavior vitro. More strikingly, readily formed with enhanced tumor at both...
Importance Prostate cancer screening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment. Objective To evaluate the effect of a single prostate-specific antigen (PSA) intervention standardized diagnostic pathway on prostate cancer–specific mortality. Design, Setting, Participants The Cluster Randomized Trial PSA Testing for Cancer (CAP) included 419 582 men aged 50 to 69 years was conducted at 573...
Recent studies based on genome-wide association, linkage, and admixture scan analysis have reported associations of various genetic variants in 8q24 with susceptibility to breast, prostate, colorectal cancer. This locus lies within a 1.18-Mb region that contains no known genes but is bounded at its centromeric end by FAM84B telomeric c-MYC, two candidate cancer genes. To investigate the specific loci cancers, we genotyped nine previously cancer-associated single-nucleotide polymorphisms...
Urothelial carcinoma of the bladder (UCC) is a common disease that arises by at least two different molecular pathways. The biology UCC incompletely understood, making management this difficult. Recent evidence implicates regulatory role for microRNA in cancer. We hypothesized altered expression contributes to carcinogenesis. To test hypothesis, we examined 322 microRNAs and their processing machinery 78 normal malignant urothelial samples using real-time rtPCR. Genes targeted differentially...
PARP inhibitors are currently being used in clinical trials to treat BRCA1- or BRCA2-defective tumors, based on the synthetic lethal interaction between PARP1 and BRCA1/2-mediated homologous recombination (HR). However, molecular mechanisms that drive this lethality remain unclear. Here, we show increased levels of Mre11, a key component MRN (Mre11-Rad50-Nbs1) complex plays role restart stalled replication forks enhanced resection at BRCA2-deficient cells. cells also showed hypersensitivity...
<b>Objectives</b> To measure the effect of adverse events within 35 days transrectal ultrasound guided biopsy from perspective asymptomatic men having prostate specific antigen (PSA) testing; to assess early attitude re-biopsy; estimate healthcare resource use associated with due biopsy; and develop a classification scheme for reporting after biopsy. <b>Design</b> Prospective cohort study (Prostate Biopsy Effects: ProBE) nested Prostate Testing Cancer Treatment (ProtecT) study....
Abstract Ionizing radiation is a potent carcinogen, inducing cancer through DNA damage. The signatures of mutations arising in human tissues following vivo exposure to ionizing have not been documented. Here, we searched for 12 radiation-associated second malignancies different tumour types. Two somatic mutation characterize irrespective type. Compared with 319 radiation-naive tumours, tumours carry median extra 201 deletions genome-wide, sized 1–100 base pairs often microhomology at the...
Abstract It remains elusive whether some of the associations identified in genome-wide association studies prostate cancer (PrCa) may be due to regulatory effects genetic variants on CpG sites, which further influence expression PrCa target genes. To search for sites associated with risk, here we establish models predict methylation (N = 1,595) and conduct analyses risk (79,194 cases 61,112 controls). We identify 759 showing an association, including 15 located at novel loci. Among those 42...
Prostate cancer is a major public health problem with considerable uncertainties about the effectiveness of population screening and treatment options. We report study design, participant sociodemographic clinical characteristics, initial results testing diagnostic phase for Treatment (ProtecT) trial, which aims to investigate treatments localised prostate cancer.